Staphylococcal entertotoxins of the enterotoxin Gene cluster (egcSEs) induce nitrous oxide- and cytokine dependent tumor cell apoptosis in a broad panel of human tumor cells by David S. Terman et al.
ORIGINAL RESEARCH ARTICLE
published: 13 August 2013
doi: 10.3389/fcimb.2013.00038
Staphylococcal entertotoxins of the enterotoxin gene
cluster (egcSEs) induce nitric oxide- and cytokine
dependent tumor cell apoptosis in a broad panel
of human tumor cells
David S. Terman1*, A. Serier2, O. Dauwalder2,3, C. Badiou2, A. Dutour4, D. Thomas2, V. Brun5,
J. Bienvenu6, J. Etienne2,3, F. Vandenesch2,3 and G. Lina2,3*
1 Molecular Genetics Program, Jenomic Research Institute, Carmel, CA, USA
2 CIRI, International Center for Infectiology Research, LabEx Ecofect, Université Lyon1, Inserm U1111, Ecole Normale Supérieure de Lyon, CNRS UMR5308,
Lyon, France
3 Centre National de Références des Staphylocoques, Hospices Civils de Lyon, Bron, France
4 Unité INSERM U590 équipe Cytokines et Cancer, Centre Léon Bérard, Lyon, France
5 Laboratoire d’Etude de la Dynamique des Protéomes, U880 CEA/DSV/iRTSV/INSERM/UJF, Grenoble Cedex, France
6 Laboratoire d’Immunologie, Centre de Biologie et Pathologie Sud, Hospices Civils de Lyon, Chemin du Grand Revoyet, Pierre Benite, France
Edited by:
Martin J. McGavin, University of
Western Ontario, Canada
Reviewed by:
John McCormick, University of
Western Ontario, Canada
Victor J. Torres, New York University
School of Medicine, USA
*Correspondence:
David. S. Terman, Molecular
Genetics Program, Jenomic
Research Institute, Seventh Avenue
and Lincoln Street, Building 1,
PO Box 6447, Carmel, CA 93953,
USA
e-mail: dst@sbcglobal.net;
G. Lina, Staphylococcal
Pathogenesis, INSERM U1111,
Domaine de la Buire, 7 rue
Guillaume Paradin, 69008 Lyon,
France
e-mail: gerard.lina@chu-lyon.fr
The egcSEs comprise five genetically linked staphylococcal enterotoxins, SEG, SEI, SElM,
SElN, and SElO and two pseudotoxins which constitute an operon present in up to 80%
of Staphylococcus aureus isolates. A preparation containing these proteins was recently
used to treat advanced lung cancer with pleural effusion. We investigated the hypothesis
that egcSEs induce nitric oxide (NO) and associated cytokine production and that these
agents may be involved in tumoricidal effects against a broad panel of clinically relevant
human tumor cells. Preliminary studies showed that egcSEs and SEA activated T cells
(range: 11–25%) in a concentration dependent manner. Peripheral blood mononuclear
cells (PBMCs) stimulated with equimolar quantities of egcSEs expressed NO synthase
and generated robust levels of nitrite (range: 200–250μM), a breakdown product of
NO; this reaction was inhibited by NG-monomethyl-L-arginine (L-NMMA) (0.3mM), an
NO synthase antagonist. Cell free supernatants (CSFs) of all egcSE-stimulated PBMCs
were also equally effective in inducing concentration dependent tumor cell apoptosis
in a broad panel of human tumor cells. The latter effect was due in part to the
generation of NO and TNF-α since it was significantly abolished by L-NMMA, anti-TNF-α
antibodies, respectively, and a combination thereof. A hierarchy of tumor cell sensitivity
to these CFSs was as follows: lung carcinoma > osteogenic sarcoma > melanoma >
breast carcinoma > neuroblastoma. Notably, SEG induced robust activation of NO/TNFα-
dependent tumor cell apoptosis comparable to the other egcSEs and SEA despite TNF-α
and IFN-γ levels that were 2 and 8 fold lower, respectively, than the other egcSEs and
SEA. Thus, egcSEs produced by S. aureus induce NO synthase and the increased NO
formation together with TNF-α appear to contribute to egcSE-mediated apoptosis against
a broad panel of human tumor cells.
Keywords: Staphylococcus aureus, egcSE superantigens, nitric oxide, tumor cell apoptosis
INTRODUCTION
Staphylococcus aureus produces a broad range of exoproteins,
including staphylococcal enterotoxins and staphylococcal-like
enterotoxins (SEs and SEls; respectively). To date, 23 different
SEs have been described: they are designated SE A to X. All these
toxins share superantigenic properties by stimulating a large pro-
portion of T cells after binding to the major histocompatibility
complex (MHC) class II molecule and crosslinking specific vβ
regions of the T-cell receptor (TCR). This interaction results in
polyclonal T-cell activation and massive secretion of cytokines
such as interleukin-2 (IL)-2, interferon gamma (IFN-γ), tumor
necrosis factor alpha (TNF-α), and nitric oxide (NO) (Marrack
and Kappler, 1990). Several members of this group have been
implicated in the pathogenesis of toxic shock syndrome and food
poisoning, and have shown anti-tumor activity in animal mod-
els (Bohach, 2006; Terman et al., 2006). The egcSEs comprise five
genetically linked staphylococcal enterotoxins, SEG, SEI, SElM,
SElN and SElO and two pseudotoxins which constitute an operon
present in up to 80% of S. aureus isolates (Jarraud et al., 2001;
Becker et al., 2003). The egcSEs are structurally homologous and
phylogenetically related to classic SEA-E and exhibit unique vβ
signatures (Jarraud et al., 2001). Despite their prevalence and
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broad distribution, human serum levels of neutralizing antibod-
ies directed against the egcSEs are significantly lower than those
directed to the classic SEs (Holtfreter et al., 2004). This has been
ascribed to defective mRNA transcription and impaired extra-
cellular secretion (Grumann et al., 2008; Xu and McCormick,
2012). Interestingly, septicemia associated with the egcSEs has
been reported to be less severe clinically than that linked to the
classic SEs (Ferry et al., 2008).
Nitric Oxide (NO) is a pleiotropic molecule that mediates a
broad spectrum of biologic functions including vasodilatation,
neurotransmission, and immune defense (Moncada and Higgs,
1993; Bogdan, 2001). NO is produced by mammalian cells from
one of the NG-guanidino nitrogens of L-arginine, in a reaction
catalyzed by a NADPH-dependent dioxygenase and referred to as
NO synthase (Kwon et al., 1990). The latter can exist in at least
two distinct isoforms the first of which is a calcium-dependent
NO synthase present mainly in neuronal cells (Bredt and Snyder,
1990) and vascular endothelial cells (Förstermann et al., 1991).
The second enzyme is a calcium-independent inducible NO
synthase found in macrophages (Marletta et al., 1988), hepato-
cytes (Billiar, 1990), endothelial cells (Radomski et al., 1990),
and smooth muscle cells (Busse and Mülsch, 1990) after acti-
vation by bacterial lipopolysaccharide (LPS) or cytokines. NO
from inducible NO synthase is responsible for killing microbial
pathogens and tumor cells by activated macrophages (Hibbs et al.,
1987, 1988; Nathan and Hibbs, 1991) and is further involved in
the pathogenesis of LPS- or cytokine-induced hypotension and
shock (Thiemermann and Vane, 1990). Tumor-associated NO,
produced by tumor cells and/or host cells that permeate tumors,
exerts both inhibitory and activating effects on carcinogenesis,
tumor growth, angiogenesis, and metastases that appear to be
concentration dependent. For example, activated macrophages
and endothelial cells may produce cytotoxic levels of NO in vitro
and prevent tumor growth and metastasis, presumably by killing
tumor cells arrested or passaging through blood vessels or sinu-
soids (Hibbs et al., 1987; Xie and Fidler, 1998; Bogdan, 2001).
Over-production of endogenous NO by tumor cells is auto-
cytotoxic and suppresses tumor growth and metastasis (Hibbs
et al., 1987; Xie and Fidler, 1998; Shi et al., 1999; Motterlini et al.,
2000; Fukumura et al., 2006; Ma et al., 2010). Conversely, low
levels of NOS II expression appear to promote tumor progres-
sion by interdicting tumor cell apoptosis (Billiar, 1990), altering
blood vessel formation and tumor vasomotor tone (Busse and
Mülsch, 1990; Radomski et al., 1990). The net effect of NO on
tumor growth or apoptosis depends not only on its source and
relative levels but also on the degree of activation of HIF1-α,
heme oxygenase-1 (HO-1) and VEGF in the tumor microen-
vironment (Tamir and Tannenbaum, 1996; Ambs et al., 1997;
Fukumura and Jain, 1998; Wink et al., 1998; Xie and Fidler,
1998).
Superantigens have been shown to induce tumor cell cyto-
toxicity in vitro and in vivo using several mechanisms. These
include superantigen dependent cellular cytotoxicity (SDCC)
wherein SAgs efficiently bind MHC class II-positive tumor cells
and subsequently trigger human T cell proliferation and dif-
ferentiation into cytotoxic T cells that kill tumor cells in a
perforin/granzyme dependent manner (Dohlsten et al., 1995).
In addition, MHCII deficient tumor cells are activated by
selected SEs to express CD-54 which costimulates T cells in a
vβ specific manner (Lamphear et al., 1998). T cell activation
under these conditions may also be enhanced via a newly rec-
ognized B7- domain present in selected SEs which interfaces
with T cell costimulatory receptor CD28 (Arad et al., 2011).
Moreover, SAgs activated T cells and monocytes also produce
various cytolytic cytokines notably IFN-γ, TNF-α, IL-2 which
alone or together with nitrous oxide can induce cytotoxicity
in both MHCII+ and MHCII- tumor cells (Fast et al., 1991;
Dohlsten et al., 1993). Whereas SDCC is effective only against
MHCII+ tumor cells (largely B cell lymphomas), cytokines
and NO are able to kill MHCII− carcinomas, fibrosarcomas
and mastocytomas (Fast et al., 1991; Dohlsten et al., 1993,
1995).
Together with neutralizing antibodies against superantigens,
the very same cytokines that mediate tumoricidal effects are con-
sidered to be the major factors underlying the constitutional
and hemodynamic toxicity of the SEs in vivo (Bette et al., 1993;
Miethke et al., 1993; Giantonio et al., 1997; Cheng et al., 2004).
In the last decade, modification of SEA’s MHCII binding affin-
ity has led to reduced toxicity in vivo (Abrahmsen et al., 1995;
Erlandsson et al., 2003). Newer versions of SEA devoid of epi-
topes for preexisting neutralizing antibodies are presently being
tested in clinical trials against renal cell carcinoma. Importantly,
naturally occurring antibodies against the egcSEs were found in
sera of less than 5% of human sera compared to 50–80% for the
classic SEs (Holtfreter et al., 2004).
Here, we examined the ability of egcSEs to generate tumo-
ricidal molecules from PMBCs. In addition, we identified such
products in cell free supernatants and investigated their ability to
induce cytotoxicity against a broad panel of human tumor cells.
These findings unveil an efficient NO and cytokine dependent
tumor killing mechanism conserved in egcSEs in the presence of
diverse levels of T cell activation and TH-1 cytokines.
MATERIALS ANDMETHODS
PREPARATIONOF RECOMBINANT SEs
SEA, SEG, SEI, SElM, SElN and SElO were produced in
Escherichia coli M15 as His-tagged recombinant toxins and puri-
fied by affinity chromatography on a nickel affinity column
according to the supplier’s instructions (New England Biolabs,
Ipswich, USA) as previously described (Thomas et al., 2009).
Protein purity was verified by SDS-PAGE. LPS was removed
from toxin solutions by affinity chromatography (Detoxi-GEL
endotoxin Gel®, Pierce Rockford, USA). The QCL-1000 Limulus
amebocyte lysate assay® (Cambrex-BioWhittaker, Walkersville,
USA) showed that the endotoxin content of the recombinant SAg
solutions was less than 0.005 units/mL.
TUMOR CELLS
Laryngeal squamous cell carcinoma cell line Hep-2 and human
non-small cell lung adenocarcinoma CRL5800 were obtained
from cell library (IFR128, Lyon, France). Osteogenic sarcoma
CRL1547, human breast cancer cell line MDA-MB-549, human
neuroblastoma cell line SK-N-BE and human melanoma PLA-
OD were a gift from Raphael Rousseau (Centre Leon Berard,
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Lyon, France). They were cultured in DMEM (Gibco, Invitrogen
Corporation, Cergy Pontoise, France) supplemented with 10%
fetal calf serum (BioWest, Paris, France), 100 U/mL penicillin
and 100μg/mL streptomycin. For SK-N-BE cells, the medium
was supplemented with 1% non-essential amino acids (Gibco,
Invitrogen Corporation, Cergy Pontoise, France).
ISOLATION OF HUMANMONONUCLEAR CELLS
Blood packs were obtained from healthy donors through a con-
vention with Etablissement Français du Sang after a written
informed consent and according to Declaration of Helsinki prin-
ciples. Peripheral blood mononuclear cells (PBMCs) were iso-
lated by Ficoll-Paque Plus® density gradient centrifugation (GE
Healthcare Life Science, Orsay, France) and were washed with
Ca- and Mg- free PBS. Cell viability was measured with the try-
pan blue exclusion test (>98%). The cells were washed in RPMI
1640 medium (Gibco, Invitrogen Corporation, Cergy Pontoise,
France).
T CELL ACTIVATION
T cell activation with various SEs was assayed by measuring
surface CD69 expression. Briefly, PBMCs (106 cells/mL) were
incubated with SEA, SEG, SEI, SElM, SElN or SElO (1 pg/mL
to 10 ng/mL) in Eagle’s minimum essential medium (EMEN)
containing 10% heat-inactivated FCS (Gibco Invitrogen, Paisley,
UK) for 24 h at 37◦C in humidified air with 5% CO2. EMEN
and 100μg/mL of phytohaemagglutinin (PHA) (Sigma-Aldrich,
Saint Quentin Fallavier, France) were used as negative and posi-
tive control, respectively. Activated PBMCs were incubated with a
mixture of anti-CD3 conjugated to cyanin-5-PE (Dako, Glostrup,
Denmark) and anti-CD69 conjugated to PE (Beckman Coulter,
Miami, FL). The cells were then analyzed with a FACScan® flow
cytometer (BD Biosciences, San Jose, CA), and the results were
expressed as the percentage of CD3+ lymphocytes expressing
CD69.
CYTOTOXICITY ASSAYS
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) cytotoxic assay was performed to investigate the effect
of stimulated PBMCs supernatants on cell viability (Mosmann,
2003). Tumor cells, 105 cells/well, were seeded in 96-well plates
and incubated with 10%, 20%, 50% or 100% of supernatants
from SE-stimulated or unstimulated PBMCs. After 1–4 days,
10μL of MTT solution (5mg/mL) (Invitrogen Corporation,
Cergy Pontoise, France) was added to culture wells and plates
were incubated for 3 h at 37◦C. Supernatant was removed and
100μL of 0.04 N HCl in isopropanol was added to each well
before reading optical density at 540 nm with an ELISA-Reader
(Bio-Rad, Marne la Coquette, France). In some experiments,
100μg/mL PHAwas used as positive control for T cell activation.
Cell toxicity data are expressed as percent of the mean value
obtained for untreated cells.
ANNEXIN V-FITC/PROPIDIUM IODIDE (PI) STAINING
Tumor cells, 105 cells/well, were seeded in 96-well plates and incu-
bated with 10% of SEs-stimulated PBMCs supernatant. After 4,
12, and 24 h, cells were harvested, washed with serum-containing
medium and centrifuged at 3000 rpm for 5min. The supernatant
was discarded and the pellet was resuspended in 500μL of 1×
binding buffer. The sample solution was incubated with 1μL of
5× FITC-conjugated annexin V (Abcam, Paris, France) and 1μL
of propidium iodide (PI) (Becton Dickinson, Le Pont de Claix,
France) in the dark for 10min at room temperature. The sam-
ples were analyzed using FACScanto II® flowcytometer (Becton
Dickinson, Le Pont de Claix, France). Data analysis was per-
formed with the FacsDiva® software (Becton Dickinson, Le Pont
de Claix, France).
Nitric Oxide (NO) assay
NO production was assessed by measuring the accumulated lev-
els of nitrite in the supernatant with Griess reagent as previously
described (Xie et al., 1995). Briefly, 100μL of Griess reagent
(1% sulfanilamide, 0.1% naphthylethylenediamine dihydrochlo-
ride, and 2.5% H3PO4) was added to 300μL of the cell culture
supernatant for 30min at room temperature. Optical densities
were read on a spectrophotometer at 548 nm. The values of NO
concentration in the culture samples were obtained from stan-
dard curve of sodium nitrite solutions. For NO inhibition assays,
PBMCs were incubated with or without a NO synthase inhibitor,
L-NG-monomethyl arginine citrate (L-NMMA) (Sigma-Aldrich,
Saint-Quentin Fallavier, France), for 2 h prior to stimulation by
SEs (final concentration 3mM). NO was quantified in super-
natants as described above. Toxicity was analyzed by annexin-V
and PI measurements as described above.
Cytokine assays
Levels of the cytokines IL-2, IL-4, IL-10, IL-12-p70, IL-17, IFN-γ,
TNF-α, and Granulocyte Macrophage-Colony Stimulating Factor
(GM-CSF) were measured in supernatants of PBMCs (106
cells/mL) incubated with 1 pg/mL of SEA, SEG, SEI, SElM, SElN
or SElO in EMEM containing 10% heat-inactivated FCS (Gibco
Invitrogen, Paisley, UK) for 24 h at 37◦C in humidified air with
5% CO2, using Milliplex® kits based on Luminex® technology
(Millipore, Molsheim, France). EMEM and 100μg/mL PHAwere
the negative and positive control, respectively.
Neutralizing antibodies against TNF-α
PBMC supernatants were incubated with and without 30μg/mL
of mouse neutralizing polyclonal anti-TNF-α antibody (Abcys,
Paris, France) for 18 h at 22◦C before carrying out the cyto-
toxic assays described above. Recombinant TNF-α, (Abcam, Paris,
France), 50 ng/mL was used as positive control.
Statistical analysis
The statistical analyses were based on Student t-test or Wilcoxon
test for non-parametric analysis. The level of statistical signif-
icance was set at 0.05. The tests were carried out with SPSS
Statistics® version 19 software (IBM France, Bois Colombes,
France).
RESULTS
egcSEs INDUCE T CELL CD69 EXPRESSION
CD69, a C-type lectin, disulfide linked homodimer is the earliest
T cell surface activation receptor appearing even before cytokine
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production (Sutkowski and Huber, 2003). It is activated by super-
antigens, cytokines, and PHA. Thus, we investigated the ability of
SEA and our recombinant egcSEs to activate CD69 expression in
T cells obtained from 3 healthy donors. We noted a hierarchy of
T cell activation as follows: SEA > SEI > SEG > SEM > SEO >
SEN. Overall, SEA activated a larger number of T cells (26%) than
all of egcSEs (p = 0.005). Among the egcSEs, SEI and SEG were
the most effective T cell stimulants, activating 19 and 23% of rest-
ing T cells respectively, levels that were significantly higher than
the SEM, SEN, and SEO (p = 0.019) (Figure 1). These findings
are consistent with the T cell activation by egcSEs demonstrated
previously using a T cell proliferation assay (Grumann et al.,
2008).
SUPERNATANTS FROM egcSE-ACTIVATED PBMCs KILL A BROAD
SAMPLING OF HUMAN TUMOR CELLS
We examined the ability of supernatants from egcSE- and SEA-
activated PBMCs to kill a broad sampling of human tumor cell
lines. In preliminary experiments, Hep-2 squamous carcinoma
cells were incubated for 96 h with various dilutions of super-
natants of PBMCs that had been stimulated for 24–96 h with each
egcSE, SEA or PHA. All supernatants from SE-stimulated PBMCs
showed significant time and dose dependent cytotoxicity for each
incubation time exceeding that of the control supernatant from
unstimulated control PBMCs (p < 0.001) (Figure 2) (data 50%
and 100% not shown). Supernatants from PBMCs incubated with
SEs for 72 h consistently produced greater Hep-2 cell cytotoxicity
than those supernatants similarly incubated for 48 h (p < 0.001).
Thus, for subsequent experiments using other tumor cell lines we
FIGURE 1 | Expression of early T cell surface marker CD69 after
incubation of human PBMCs with SEA and egcSEs. CD69 expression
was measured on T lymphocytes (CD3+) after 24h of incubation with
PBMCs (106 cells/mL) in presence of SEA, SEG, SEI, SElM, SElN, or
SElO (0–10ng/mL). PHA (100μg/mL) was used as positive control.
Results are shown as the mean ± SEM for each point (n = 3 independent
experiments). Asterisks indicate statistical significance compared to SEA.
elected to use supernatants from PBMCs incubated with SEs for
72 hours.
Having shown that supernatants from both egcSEs- and SEA-
stimulated PBMCs were cytotoxic for Hep2 squamous cell car-
cinoma cells, we determined whether the cytotoxicity of these
supernatants could also be demonstrated in broad sampling of
the major human tumor histotologic types which included lung
and breast carcinoma, melanoma, neuroblastoma, and osteogenic
sarcoma cells. All egcSEs and SEA supernatants were equally
effective in inducing significant concentration dependent cyto-
toxicity against all five human tumor cell lines compared to the
unstimulated control (p < 0.005) (Figure 3). A hierarchy of sen-
sitivity of the tumors to the cytotoxicity of the SE-stimulated
PBMC supernatants is as follows: lung carcinoma > osteogenic
sarcoma > melanoma > breast carcinoma > neuroblastona
(Figure 3).
By contrast, we did not observe any direct toxic effect of 1
pg to 10 ng/mL of SEA and egcSE’s on any the tumor cell lines
tested herein (data not shown). To determine how tumor cell lines
died upon addition of SE-activated PBMC supernatants, Annexin
V, and PI staining was performed on Hep-2 tumor cells treated
with 10% supernatants from SEA and egcSE-stimulated PBMCs.
The percentage of annexinV+ cells was 10–45 fold higher than
the percentage of IP+ annexinV− cells at levels identical to those
observed with unstimulated PBMC supernatants. These results
suggest that upon addition of SE activated PBMC supernatants,
cell lines died mainly by apoptosis.
NITROUS OXIDE GENERATION FROM egcSE-ACTIVATED PBMCs
Next we determined whether NO could be induced by egcSE-
activated PBMCs and mediate a tumoricidal response. PBMCs
stimulation by egcSEs and SEA was associated with a signifi-
cant increase in nitrite production (p < 0.001) with no difference
between toxins (p > 0.05) (Figure 4). As expected, the addition
of nitrous oxide synthase inhibitor L-NMMA to PBMCs inhib-
ited NO induction by all toxins (p < 0.001) with no significant
differences in the degree of inhibition.
FIGURE 2 | Cytotoxicty of SEA and egcSE-stimulated PBMCs against
Hep2 squamous cell carcinoma cells. Supernatants from unstimulated
PBMCs, SEA-, SEG-, SEI-, SElM-, SElN-, or SElO-stimulated PBMCs were
added at 10% or 20% vol/vol to Hep2 squamous cell carcinoma cell
culture. After 1–4 days, cell viability was evaluated by MTT asays. Results
are shown as the mean ± SEM for each point (n = 3 independent
experiments).
Frontiers in Cellular and Infection Microbiology www.frontiersin.org August 2013 | Volume 3 | Article 38 | 4
Terman et al. egcSEs induced tumor cell apoptosis
FIGURE 3 | Cytotoxicty of SEA and egcSE-stimulated PBMCs vs. a
broad panel of human tumor cell lines is shown. Cytotoxicity of 72 h
supernatants from unstimulated PBMCs, SEA-, SEG-, SEI-, SElM-, SElN-, or
SElO-stimulated PBMCs against human non-small cell lung
adenocarcinoma CRL5800, osteogenic sarcoma CRL1547, human breast
cancer cell line MDA-MB-549, human neuroblastoma cell line SK-N-BE and
human melanoma PLA-OD were examined as described in Figure 2.
Results are mean ± SEM (n = 3 independent experiments). Asterisks
indicate statistical significance compared to the untreated PBMC control
values at 10 or 20% concentrations.
NITROUS OXIDE SYNTHASE INHIBITION OR NEUTRALIZING
ANTI-TNF-α INDIVIDUALLY OR COMBINED REDUCE(S) TUMOR CELL
CYTOTOXICITY OF SUPERNATANTS FROM egcSE-STIMULATED PBMCs
Having shown that both egcSEs and SEA induced NO production
by PBMCs, we determined whether the tumor cell cytotoxic-
ity of the supernatants could be attenuated by the addition of
nitrous oxide synthase inhibitor L-NMMA. Supernatants from
10% egcSE- and SEA-stimulated PBMCs induced tumor cell
cytotoxicity. In all cases, tumor cell apoptosis was confirmed
by annexin V-FITC/PI staining (Figure 5). Exposure of PBMCs
to L-NMMA, a competitive inhibitor of NOS, before incu-
bation with egcSEs or SEA induced a significant decrease in
tumor cell cytotoxicity of all supernatants (range: p = 0.01 for
SEA to p = 0001 for SEO) with the sole exception of SEN
FIGURE 4 | Nitrite generation from SEs-stimulated PBMCs. NO was
quantified with Griess reagent in the supernatant of PBMCs (106
cells/mL) incubated for 24h in a presence of EMEM, SEA, SEG, SEI,
SElM, SElN, or SElO, with or without NOS inhibitor, L-NMMA (300μM).
The results are mean ± SD (n = 3 independent experiments). Asterisks
indicate statistical significance compared to values obtained without the
NOS inhibitor.
FIGURE 5 | Anti- TNF-α and NO inhibitor, alone and in combination
inhibit Hep-2 tumor cells cytotoxicity induced by 10% supernatants
from SEA and egcSE-stimulated PBMCs. Hep-2 tumor cells cytotoxicity
induced by 10% supernatants from SEA and egcSE-stimulated PBMCs
before (black) or after treatment with L-NMMA (dark gray) or anti-TNF-α
antibody (light gray) or a combination of L-NMMA plus anti-TNF-α antibody
was analyzed by flow cytomerter using FITC-conjugated annexin-V and
propidium iodide (IP) staining. The results are expressed as the mean ±
SEM (n = 3 independent experiments). Asterisks indicate statistical
significance compared to values obtained before treatment with L-NMMA
or anti-TNF-α antibody.
(p = 0.85) (Figure 5). Notably, supernatants from SEG and
SEO-stimulated PBMCs showed more significant reductions in
tumor cytotoxicity (p = 0.002 and p = 0.001, respectively) than
SEA supernatants (p = 0.01) (Figure 5). We further determined
whether tumor cell cytotoxicity of all SE supernatants could
be attenuated by the addition of anti-TNF-α to L-NMMA.
The combined treatments significantly reduced the cytotoxic-
ity of SEA (p = 0.005) and three of the 5 egcSEs, namely SEG
(p = 0.009), SEI (p = 0.013) and SEO (p = 0.001) (Figure 5).
Notably, the inhibitory effects of L-NMMA and anti-TNF-α
did not completely abolish the tumor cell cytotoxicity suggest-
ing that additional tumoricidal factors are operative in this
system.
CYTOKINE PROFILES OF SUPERNATANTS INDUCED BY SE-ACTIVATED
PBMCs
Levels of cytokines TNF-α, IFN-y, IL-2, IL-4, IL-10, IL-17, and
GM-CSF produced after stimulation of PBMCs from six healthy
donors by egcSEs and SEA were measured. The absolute cytokine
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levels induced by each egcSE and canonical SEA are shown in
Table 1. Cytokine levels of egcSEs I, M, N, and SEA-activated
PBMCs were not significantly different [except for IL-4 and IL-10
after stimulation with SEO (p > 0.05)]. SEA induced significantly
higher levels of cytokines than SEG with mean cytokine values 5,
8, 2, 6, 7, and 2 fold higher than SEG for GM-CSF, INF-γ, IL-2,
IL-4, IL-10, IL-17, and TNFα, respectively (range p = 0.01–0.04,
except for TNF-α).
DISCUSSION
Our results demonstrate that egcSEs activate 11–21% or resting T
cells and that cell free supernatants (CFSs) from egcSE-stimulated
PBMCs induced NO synthase activation and robust generation of
NO along with TH-I TH-2 cytokines. Such CFSs from all egcSEs
induced an equal degree of annexin positive apoptosis in a broad
panel of clinically relevant human tumor cells with a hierarchy of
sensitivity: lung carcinoma> osteogenic sarcoma>melanoma>
breast carcinoma > neuroblastoma. The apoptotic effect of the
egcSE CSFs appears to be mediated in part by NO and TNF-α
since NO synthase inhibitor L-NMMA and anti-TNF-α antibod-
ies significantly inhibited the tumor cell cytotoxicity.Moreover, all
egcSE CFSs with the exception of SEG contained substantial levels
of additional TH-1 cytokines such as IFN-γ that could contribute
to the tumor cell cytotoxicity.
Hibbs et al., was the first to demonstrate that NO could
inhibit tumor cell growth and/or induce tumor cell death by
activated macrophages (Hibbs et al., 1987). Subsequently, NO-
mediated tumor cell cytotoxicity has been demonstrated by a
variety of immune cells including natural killer cells, T-cells, and
endothelial cells (Albina and Reichner, 1998). Fast et al. showed
that SEB and TSST-1-induced NO and TNF-α derived from
activated macrophages could promote cytotoxicity of murine
fibrosarcoma and mastocytoma cells (Fast et al., 1991). Herein,
we extend these findings by showing that NO from egcSE-
stimulated PBMCs contribute to the cytotoxicity of human tumor
cells.
NO donors such as L-arginine from both endogenous and
exogenous sources have been shown to exert an inhibitory action
on the proliferation of tumor cells, such as breast cancer, masto-
cytoma, neuroblastoma, epidermoid carcinoma, pheochromocy-
toma, colon carcinoma, and pancreatic carcinoma cells in vitro
(Maragos et al., 1993; Estrada et al., 1997; Buga et al., 1998;
Gansauge et al., 1998; Pervin et al., 2001; Murillo-Carretero
et al., 2002; Ruano et al., 2003; Tesei et al., 2003; Ciani et al.,
2004; Huguenin et al., 2004; Bal-Price et al., 2006). The stim-
ulatory or inhibiting behavior of NO appears to be related to
the distinct concentrations of NO attained under different exper-
imental conditions. For instance, iNOS-generated NO present
in excess of 300 nmol/L promotes DNA damage, gene muta-
tion and apoptosis via increased phosphorylation of p53 and
expression of MKP-1, inhibition of phosphorylation of pro-
tein kinase C (PKC), extracellular-signal-regulated protein kinase
(ERK) and JUN (Pervin et al., 2003; Jones et al., 2004; Thomas
et al., 2004; Ridnour et al., 2005; Fukumura et al., 2006). NO
donors have been shown to induce apoptotic cell death by
inhibiting NF-κB by phosphorylation of p50 via S-nitrosylation
(Marshall and Stamler, 2001), binding to iron-sulfur centers
and inhibiting aconitase, complex I/complex II of the mito-
chondrial respiratory chain, or ribonucleotide reductase (Stuehr
and Nathan, 1989; Lepoivre et al., 1990). In lower concentra-
tions, tumor cell NO promotes tumor growth, neovascularization
and invasiveness by induction of p53 mutations, upregulation
of vascular endothelial growth factor resulting in neovascu-
larization, increased vascular permeability and vasodilatation
(Krischel et al., 1998; Ulibarri et al., 1999; Frank et al., 2000;
Luczak et al., 2004; Wai et al., 2006). In the present study, a
low dose of each egcSE induced robust nitrite concentrations
of 200–250μM suggesting that these agents may be capable of
inducing a sufficient quantity of NO to exert a tumoricidal effect
in vivo.
In vivo, exogenous NO or endothelial-cell derived NO in
higher concentrations appears to present a tumoricidal barrier
inimical to tumor cell dissemination. Selective genetic or pharma-
cological inhibition of eNOS or iNOS or enzymatic induction of
NO deficiency in tumor cells diminishes VEGF, HO-1, andHIF1α
activation and consequent tumor cell proliferation and angio-
genesis (Kimura et al., 2000; Motterlini et al., 2000; Naughton
et al., 2002; Kasuno, 2004). Local release of NO in endothelial
cells, liver sinusoids, or pulmonary circulation causes apoptosis
of the disseminated tumor cells at these sites (Fukumura et al.,
1996; Wang et al., 2000, 2007; Qiu et al., 2003; Qi et al., 2004).
Finally, daily intraperitoneal injections of NO-producing nitrova-
sodilators isosorbide mono-and dinitrate resulted in a significant
decrease of the size of the primary tumor and a reduction in
the number and size of spontaneous lung metastases (Pipili-
Synetos et al., 1995). Thus, NO donors delivered parenterally or
Table 1 | Level of cytokines in supernatants of PBMC stimulated by SEA, SEG, SEI, SElM, SElN, and SElO.
Cytokines (mean ± SEM)
GM-CSF INF-γ IL-2 IL-4 IL-10 IL-17 TNF-α
SEA 474 ± 148 1816 ± 421 1210 ± 346 46 ± 8 674 ± 121 98 ± 19 852 ± 217
SEG 91 ± 33* 102 ± 38* 137 ± 43* 7 ± 2* 51 ± 15* 14 ± 4* 437 ± 162
SEI 652 ± 198 3344 ± 481 1354 ± 328 43 ± 5 366 ± 43 103 ± 20 1189 ± 262
SElM 282 ± 90 1249 ± 331 853 ± 226 18 ± 2 145 ± 17 50 ± 10 637 ± 199
SElN 290 ± 98 965 ± 326 826 ± 217 17 ± 3 232 ± 60 69 ± 22 692 ± 248
SElO 112 ± 37 888 ± 330 251 ± 33 8 ± 1* 76 ± 19* 41 ± 13 590 ± 217
Results are shown as the mean ± SEM for each point (n = 7 experiments with different blood donors). Asterisks indicate statistical significance compared to SEA.
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released from activated endothelial cells in sufficient concentra-
tion appears to be capable of inducing local tumor cell death and
limiting tumor metastases.
In our study, NO and TNF-α in the CSF exhibited an addi-
tive effect in tumor cell cytotoxicity. Indeed, all of the egcSEs
induced robust levels of NO andTNF-αwith the exception of SEG
as discussed below. TNF-α has direct effects on a variety of cell
types and has been shown to work together with NO in tumor
cell cytotoxicity (Laster et al., 1988; Estrada et al., 1992). NO is
known to sensitize tumor cells to TNF-α -mediated apoptosis via
specific disruption of the TNF-α -induced generation of hydro-
gen peroxide and subsequent inhibition of the NF-κB dependent
expression of anti-apoptotic genes (Schreck et al., 1992; Hong
et al., 1997). Moreover, G1 arrest has been attributed to endoge-
nous NO following activation by TNF-α, IFN-γ and IL-1 in breast
and pancreatic carcinoma cells (Gansauge et al., 1998; Pervin
et al., 2001). Furthermore, all of the egcSEs except SEG were
also shown herein to be potent inducers of IFN-γ that could
contribute to the tumor cytotoxic response.
In addition to its tumor killing properties, TNF-α has also
been identified as the major cause of SE-induced toxicity in mice
(Bette et al., 1993; Miethke et al., 1993). In previous cancer tri-
als, the systemic toxicity of SEA was presumed to be related to
TNF-α (Giantonio et al., 1997; Cheng et al., 2004). As shown
herein, while SEG induced robust production of nitrite from
PBMCs and robust tumor cell cytotoxicity, it also displayed sub-
stantially lower quantities of TNF-α and IFN-γ relative to other
egcSEs. Interestingly, a supernatant from S. aureus producing SEG
together with the other egcSEs used in a recent cancer trial exhib-
ited minimal systemic toxicity (Ren et al., 2004). SEG’s potent
T cell activation (comparable to SEA) coupled with its signif-
icantly reduced cytokine levels (relative to SEA and the other
egcSEs) is reminiscent of split T cell responses when classic
peptide antigen is presented to T cells in the absence B7 cos-
timulation (Schweitzer and Sharpe, 1998). In this context, wild
type SEA has been shown to possesses an intirisic costimula-
tory B7-like sequence in its conserved β-strand/hinge/α -helix
domains that engages and activates the T cell costimulatory CD28
homodimer resulting in T cell cytokine secretion; mutation of
this sequence resulted in attenuated cytokine production (Arad
et al., 2011). SEG possesses several amino acid substitutions
in this conserved sequence which could alter its topographic
interface with T cell CD28 resulting in reduction in cytokine
levels noted herein. These findings suggest that the nature of
SEG’s T cell response depends not only on its affinity for MHCII
but also on the strength of its intrinsic costimulatory interac-
tion with T cell CD28. SEG’s retention of NO-dependent tumor
cell cytotoxicity and robust T cell activation in the presence
of low cytokine levels makes it a promising model for such
investigation.
Neutralizing antibodies against superantigens are considered
to be the major factors underlying superantigen therapy fail-
ure. It was recently confirmed in the completed Phase II/III
trial using a hybrid SEA/SEE120 superantigen (fused to a mouse
monoclonal Fab targeting the 5T4 antigen on tumor cells) that
SEA/SEE120 did not improve overall survival in advanced renal
cell cancer (Hawkins et al., 2013). The ineffectiveness of this drug
was likely due to the higher than expected levels of pre-existing
anti-SEA/SEE120 antibodies because a small subgroup of patients
with low levels of anti-SEA/SEE120 antibodies did apparently
demonstrate longer survival. Importantly, prevalence of antibod-
ies against egcSEs including SEG is much lower than antibodies
against classical SEs (Holtfreter et al., 2004). Our results demon-
strating SEG’s retention of NO-dependent tumor cell cytotoxicity
and robust T cell activation in the presence of low cytokine levels
suggests SEG may be more appropriate for superantigen therapy
in cancer.
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